Biogen CEO Plots A Slow Return To Growth As Revenue Set To Shrink Again In 2023
Cost Cuts, R&D Prioritization, Deals All On The Table
https://scrip.pharmaintelligence.informa.com/SC147918/Biogen-CEO-Plots-A-Slow-Return-To-Growth-As-Revenue-Set-To-Shrink-Again-In-2023